OpenAlex
PricingAboutJobs
Log inGet started
Work

Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.

PubMed

Year: 2019
Type: article
Source: PubMed
Authors: Ana Valido, Joana Silva-Dinis, Maria João Saavedra, Inês Iria, João Gonçalves, João Paulo Lopes, João Eurico Fonseca
Institutions: Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, University of Lisbon
Language: English

Topic: Biosimilars and Bioanalytical Methods
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: infliximab, CT-P13, brand-name drugs, inflammatory arthritis, rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, anti-drug antibodies, treatment efficacy, cost reduction, immunogenicity, disease activity, ankylosing spondylitis, drug cost reduction, treatment discontinuation
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2994431592
FWCI: 1.238
Cites:
Cited by: 20
Related to: 9
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security